Introduction: Breast cancer and osteoporosis, with associated increased fracture risk, are both common, with being female, increasing age and family history being the most significant risk factors. In all, 50% of female breast cancers develop in the two decades following menopause transition. Improved detection, surgical techniques and biologically targeted chemoendocrine therapy mean that survivorship is increasing. Many post-menopausal women are living with a cancer diagnosis or with the effects of cancer treatments which mimic or exacerbate menopausal symptoms for many years. Aromatase inhibitors (AIs) are widely used in the management of post-menopausal ERþve breast cancer. Their osteodetrimental effect exacerbates the post-menopausal and age-related bone loss in women, increasing fracture risk. Clarity and consensus exist in the management of increased fracture risk, and the National Cancer Survivorship Initiative encourages addressing breast cancer therapy consequences including fracture risk. Targeted strategies will reduce the financial impact of common adverse therapy events in the current resource-limited NHS economy. Methods: A dedicated Bone Health Clinic was established within the breast service. Guidelines for the management of AI-induced fracture risk were developed. A baseline DEXA scan, holistic clinical assessment including lifestyle factors, a FRAX Õ score and appropriate investigations were performed. Management plans, including lifestyle advice, patient education, antiresorptive therapy and nutritional supplements in line with established guidelines were instigated and plans for monitoring response and review of medication compliance were established. Results: One hundred ninety-six patients were assessed in the first six months. At breast cancer diagnosis, women were more likely to have a lower bone mineral density (BMD) than the normal population (osteopenia 63.2%, osteoporosis 21.3%), FRAX Õ and NOGG thresholds may underestimate risk and need for antiresorptive medication. Overall, 69% of patients had one or more underlying contributing factors to their reduced BMD as well as their breast cancer which required addressing, the commonest being a low Vitamin D (31%). Conclusions: Establishment of a clinic has resulted in clinical and cost-effective management pathway for a significant adverse therapy event which can be anticipated, responding to patient and commissioning needs and NCSI and NHS Outcomes Framework. In managing one disease, we will not leave women with another.
Clinicians' viewpoint about prescribing hormone replacement therapy to women with controlled high blood pressure
Vinod Kumar 1 and Jennifer Williamson 2 1 ST5 CSRH Trainee, University Hospitals Birmingham NHS Foundation Trust, UK 2 Menopause Lead, Birmingham Women's Hospital, UK Introduction: Despite the proven benefits of hormone replacement therapy (HRT) in controlling menopausal symptoms, there continues to be anxiety among clinicians about its use in women who also have controlled hypertension (HTN). This questionnaire survey was carried out to evaluate whether general practitioners (GPs) or gynaecologists in West Midlands prescribe or recommended the use of HRT in menopausal women with controlled HTN. Methods: An online questionnaire survey was emailed to GPs and gynaecologists in the West Midlands region. The survey was live for 12 weeks between September 2013 and November 2013. Responses were collated with SurveyMonkey Õ . Results: Overall, there were 67 respondents. Just under half (48%) of all respondents reported that in their opinion HRT raised blood pressure (BP). In all, 11% reported that they would not start HRT (either combined HRT or estradiol only HRT) in an otherwise healthy menopausal woman with well-controlled HTN. Just over one-third of the respondents (36%) would change or stop HRT, if a rise in BP was noted after the introduction of HRT. In all, 32% reported that they did not routinely measured BP before starting HRT. The commonest reported frequency of BP measurement post-HRT was three-monthly (20%) or six-monthly (24%). In all, 61% did not feel 'very confident' in prescribing HRT, mainly due to confusion caused by conflicting research findings or lack of experience. Conclusion: The study demonstrates differences amongst clinicians in their management of menopausal women with well-controlled hypertension. These women need not be denied the benefits of HRT. The blood pressure of these women receiving HRT should be checked regularly during therapy.
A mixed methods study examining how menopausal symptoms are related to a woman's body image, exercise behaviour and wellbeing Introduction: Menopause represents the change from a woman's fertile to non-fertile period, and the transition from a younger to older adult; with potential to impact how a woman thinks and feels about herself and her body, her health-related behaviour and wellbeing. This study aimed to study the relationships between menopausal symptoms, appearance evaluation, exercise behaviour, and a range of wellbeing indicators using a mixed methods approach. Methods: A mixed method design was used with full informed consent from participants. A nationwide survey was carried out with women (n ¼ 271; mean age 53, SD ¼ 4) who considered themselves to be experiencing the natural menopausal transition/climacteric to investigate the association between the variables of interest. Structural equation modelling was employed to examine these associations. A selection of these participants (n ¼ 12) were subsequently interviewed about their experiences of the menopause and put into the context of the developed model to provide potential explanations. Results: The qualitative findings helped to corroborate the relationships in the model. Menopausal symptoms were significantly negatively related to both appearance and exercise, when mediated by subjective vitality (e.g. menopausal symptoms made some women feel tired, drained, not wanting to exercise and frustrated with bodily changes). Exercise was significantly associated with self-esteem and life satisfaction, when mediated by appearance (e.g. those who did not exercise, felt worse about their bodies, and so had lower wellbeing). The interviews helped to provide further insight into positive, negative and neutral experiences of the transition and how/why this influenced perceptions, decision making and behaviour. Conclusions: Menopausal symptoms may act as a barrier to exercise participation by decreasing a woman's feelings of vitality; this in turn reduces perceptions of attractiveness, and then as a result decreases life satisfaction and self-esteem. We recommend that symptom perception, motivations to exercise, perceived control and ability to cope (with symptoms, bodily changes and the life transition more generally) are additional factors considered by researchers and healthcare professionals in the future. In sum, it is not only important to consider methods to reduce symptoms but also the impact symptoms have on health behaviour, body image and wellbeing. This presentation was awarded first prize in the Free Communications session at the British Menopause Society annual conference 2014.
An audit of bone mineral density in premature ovarian insufficiency
Lynne Robinson 1 and Roanna Dewsbury 2 1 Consultant Gynaecologist and Obstetrician, Birmingham Women's Hospital, UK 2 O&G Trainee, West Midlands, UK Introduction: Premature ovarian insufficiency (POI) is associated with a 50% higher mortality than women who undergo menopause aged 52-55 years. A significant morbidity is loss of bone mineral density (BMD) due to hypoestrogenism. Low BMD in POI is attributed mainly to the accelerated bone loss in the initial 4-5 years post menopause. Fragility fractures cost UK healthcare an estimated £1.8 billion in 2000. The gold standard treatment is estrogen replacement in the form of hormone replacement therapy (HRT) as this is effective at preventing vertebral and non-vertebral fractures. Our aim was to audit our practice of performing BMD measurements on POI patients and their subsequent treatment and follow-up. Methods: The notes of 24 POI patients (under 45 years) who had low BMD on DEXA scan in 2010-2011 at Birmingham Women's Hospital were reviewed. Data were collected on the aetiology of each patient's POI and their treatment. Results: An osteoporosis prevalence of 1.6% and osteopenia of 14% were identified, compared to 3.6% and 25.9% prevalence, respectively, in other areas of the UK. A third of cases were idiopathic or as a result of treatment of malignancy, a third were surgically induced and a third were due to genetic or medical conditions. All but one patient (96%) were on HRT. Nineteen (79%) patients had their dose recorded, of these 68% were on standard dose HRT. No changes to treatment were made as a result of the DEXA findings but plans were made for any further BMD measurement. Conclusion: We have identified that a significant proportion of our POI population have low BMD and therefore measurement of this at presentation is appropriate to aid further management and encourage compliance. Almost all our patients received HRT but emphasis should be placed on early diagnosis and initiation of standard dose HRT due to the initial rapid loss of BMD. A higher proportion of our low BMD patients had surgically induced POI. This emphasises their need for HRT post-operatively. Further research is required to investigate the relationship between low BMD and the loss of testosterone release from the postmenopausal ovary experienced in oophorectomised patients.
Comparison of efficacy of oral contraceptive pill versus hormone replacement therapy in maintenance of bone mineral density and suppression of symptoms of estrogen deficiency in premature ovarian insufficiency
Vikram Sinai Talaulikar, E Yasmin, M Davies and G Conway
Reproductive Medicine Unit, University College London Hospital, UK Introduction: The question whether oral contraceptive pills as a form of estrogen replacement have the same efficacy and physiological benefits as the hormone replacement therapy (HRT) in premature ovarian insufficiency has not yet been conclusively answered. As women with this condition are often managed with both forms of treatment alternatively, comparison between the two types of medications as regards to their efficacy becomes difficult. We sought to compare the bone mineral density (BMD) (surrogate marker of adequate estrogen replacement) and suppression of hot flushes and night sweats in these two groups of women on either form of treatment exclusively and look for any significant differences. Methods: Retrospective analysis of case records of 52 women with premature ovarian insufficiency (FSH 25 IU) due to idiopathic, autoimmune, genetic or metabolic causes was performed in a tertiary referral unit in a university teaching hospital. Comparison was performed between serial BMD measurements between women who only used the oral contraceptive pill versus those who only used the hormone replacement therapy as a form of estrogen replacement. BMD measurements were performed at two sites -lumbar spine and hip by DEXA scan and the results were expressed as percentage gain or loss in bone mass. Records were also compared to evaluate the relief from symptoms of estrogen deficiency -hot flushes and night sweats as reported at the follow-up visits. The two groups were compared for confounders such as age, body mass index, smoking, previous or family history of bone disease, age of menarche/induction of puberty, age of onset of POI. Women with concurrent medical or other endocrine problems were excluded from the study. Results: BMD at lumbar spine and femur was maintained stable or higher in the HRT group (14% and 7% higher BMD at three years) in comparison to the pill users. The dose and preparation of HRT was an important determinant of the outcome. There was better suppression of hypoestrogenic symptoms in the HRT group.
Conclusion: HRT appears to suppress symptoms of estrogen deficiency and maintain BMD more consistently than the contraceptive pill in women with POI. Larger studies with prospective designs are needed to confirm these findings. 
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